Efficacy of Human Papillomavirus 16 and 18 (HPV-16/18) AS04-Adjuvanted Vaccine against Cervical Infection and Precancer in Young Women: Final Event-Driven Analysis of the Randomized, Double-Blind PATRICIA Trial

被引：78

作者：

Apter, Dan ^{[1
]}

Wheeler, Cosette M. ^{[2
,3
]}

Paavonen, Jorma ^{[4
]}

Castellsague, Xavier ^{[5
]}

Garland, Suzanne M. ^{[6
,7
]}

Skinner, S. Rachel ^{[8
,9
]}

Naud, Paulo ^{[10
]}

Salmeron, Jorge ^{[11
,12
]}

Chow, Song-Nan ^{[13
]}

Kitchener, Henry C. ^{[14
]}

Teixeira, Julio C. ^{[15
]}

Jaisamram, Unnop ^{[16
]}

Limson, Genara ^{[17
]}

Szarewski, Anne ^{[18
]}

Romanowski, Barbara ^{[19
]}

Aoki, Fred Y. ^{[20
]}

Schwarz, Tino F. ^{[21
,22
]}

Poppe, Willy A. J. ^{[23
]}

Xavier Bosch, F. ^{[24
]}

Mindel, Adrian ^{[25
]}

De Sutter, Philippe

Hardt, Karin ^{[26
,27
]}

Zahaf, Toufik ^{[26
,27
]}

Descamps, Dominique ^{[26
,27
]}

Struyf, Frank ^{[26
,27
]}

Lehtinen, Matti ^{[28
]}

Dubin, Gary ^{[29
]}

机构：

[1] Sexual Hlth Clin, Family Federat Finland, Helsinki, Finland

[2] Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Albuquerque, NM 87131 USA

[3] Univ New Mexico, Hlth Sci Ctr, Dept Obstet & Gynecol, Albuquerque, NM 87131 USA

[4] Univ Helsinki, Dept Obstet & Ginecol, Helsinki, Finland

[5] Hosp Llobregat, Biomed Res Ctr Network Epidemiol & Publ Hlth CIBE, DIBELL, ICO,Canc Epidemiol Res Program, Catalonia, Spain

[6] Univ Melbourne, Royal Womens Hosp, Murdoch Childrens Res Inst, Microbiol & Infect Dis Dept, Melbourne, Vic, Australia

[7] Univ Melbourne, Murdoch Childrens Res Inst, Dept Obstet & Gynaecol, Melbourne, Vic, Australia

[8] Telethon Inst Child Hlth Res, Vaccine Trials Grp, Perth, WA, Australia

[9] Univ Sydney, Childrens Hosp Westmead, Discipline Paediat & Child Hlth, Sydney, NSW 2006, Australia

[10] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil

[11] Inst Mexicano Seguro Social, Unidad Invest Epidemiol, Cuernavaca, Morelos, Mexico

[12] Inst Mexicano Seguro Social, Serv Salud, Cuernavaca, Morelos, Mexico

[13] Natl Taiwan Univ, Coll Med & Hosp, Dept Obstet & Gynecol, Taipei 10764, Taiwan

[14] St Marys Hosp, Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester M13 0JH, Lancs, England

[15] Univ Estadual Campinas, Campinas, SP, Brazil

[16] Chulalongkorn Univ, Fac Med, Dept Obstet & Gynaecol, Bangkok 10330, Thailand

[17] Univ Philippines, Philippine Gen Hosp, Coll Med, Makati Med Ctr, Makati, Philippines

[18] Queen Mary Univ London, Ctr Canc Prevent, Wolfson Inst Prevent Med, London, England

[19] Univ Alberta, Edmonton, AB, Canada

[20] Univ Manitoba, Winnipeg, MB, Canada

[21] Univ Wurzburg, Acad Teaching Hosp, Stiftung Juliusspital, Cent Lab, Wurzburg, Germany

[22] Univ Wurzburg, Acad Teaching Hosp, Stiftung Juliusspital, Vaccinat Ctr, Wurzburg, Germany

[23] Univ Hosp KU Leuven Gasthuisberg, Dept Gynaecol, Leuven, Belgium

[24] Network Cooperat Canc Res RTICC, Inst Catala Oncol, IDIBELL, Canc Epidemiol Res Program, Catalonia, Spain

[25] Ctr AIDS Programme Res Soth Africa, Durban, South Africa

[26] Vrije Univ Brussel, Univ Ziekenhuis Brussel, Afdelingshoofd Gynaecol Oncol, Brussels, Belgium

[27] GSK Vaccines, Wavre, Belgium

[28] Univ Tampere, Sch Publ Hlth, FIN-33101 Tampere, Finland

[29] GSK Vaccines, King Of Prussia, PA USA

来源：

CLINICAL AND VACCINE IMMUNOLOGY | 2015年 / 22卷 / 04期

关键词：

OF-STUDY ANALYSIS; PARTICLE VACCINE; HPV-VACCINATION; FOLLOW-UP; TYPE-16; CANCER; PREVALENCE; SAFETY; IMMUNIZATION; PREVENTION;

D O I：

10.1128/CVI.00591-14

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We report final event-driven analysis data on the immunogenicity and efficacy of the human papillomavirus 16 and 18 ((HPV16/18) AS04-adjuvanted vaccine in young women aged 15 to 25 years from the PApilloma TRIal against Cancer In young Adults (PATRICIA). The total vaccinated cohort (TVC) included all randomized participants who received at least one vaccine dose (vaccine, n = 9,319; control, n = 9,325) at months 0, 1, and/or 6. The TVC-naive (vaccine, n = 5,822; control, n = 5,819) had no evidence of high-risk HPV infection at baseline, approximating adolescent girls targeted by most HPV vaccination programs. Mean follow-up was approximately 39 months after the first vaccine dose in each cohort. At baseline, 26% of women in the TVC had evidence of past and/or current HPV-16/18 infection. HPV-16 and HPV-18 antibody titers postvaccination tended to be higher among 15- to 17-year-olds than among 18- to 25-year-olds. In the TVC, vaccine efficacy (VE) against cervical intraepithelial neoplasia grade 1 or greater (CIN1+), CIN2+, and CIN3+ associated with HPV-16/18 was 55.5% (96.1% confidence interval [CI], 43.2, 65.3), 52.8% (37.5, 64.7), and 33.6% (-1.1, 56.9). VE against CIN1+, CIN2+, and CIN3+ irrespective of HPV DNA was 21.7% (10.7, 31.4), 30.4% (16.4, 42.1), and 33.4% (9.1, 51.5) and was consistently significant only in 15- to 17-year-old women (27.4% [10.8, 40.9], 41.8% [22.3, 56.7], and 55.8% [19.2, 76.9]). In the TVC-naive, VE against CIN1+, CIN2+, and CIN3+ associated with HPV-16/ 18 was 96.5% (89.0, 99.4), 98.4% (90.4, 100), and 100% (64.7, 100), and irrespective of HPV DNA it was 50.1% (35.9, 61.4), 70.2% (54.7, 80.9), and 87.0% (54.9, 97.7). VE against 12-month persistent infection with HPV-16/18 was 89.9% (84.0, 94.0), and that against HPV-31/33/45/51 was 49.0% (34.7, 60.3). In conclusion, vaccinating adolescents before sexual debut has a substantial impact on the overall incidence of high-grade cervical abnormalities, and catch-up vaccination up to 18 years of age is most likely effective.

引用

下载

页码：361 / 373

页数：13

共 50 条

[31] Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years
Schwarz, Tino F.
Spaczynski, Marek
Schneider, Achim
Wysocki, Jacek
Galaj, Andrzej
Perona, Pamela
Poncelet, Sylviane
Zahaf, Toufik
Hardt, Karin
Descamps, Dominique
Dubin, Gary
VACCINE, 2009, 27 (04) : 581 - 587
[32] Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years
Romanowski, B.
de Borba, P. Colares
Naud, P. S.
Roteli-Martins, C. M.
De Carvalho, N. S.
Teixeira, J. C.
Aoki, F.
Ramjattan, B.
Shier, R. M.
Somani, R.
Barbier, S.
Blatter, M. M.
Chambers, C.
Ferris, D.
Gall, S. A.
Guerra, F. A.
Harper, D. M.
Hedrick, J. A.
Henry, D. C.
Korn, A. P.
Kroll, R.
Moscicki, A-B
Rosenfeld, W. D.
Sullivan, B. J.
Thoming, C. S.
Tyring, S. K.
Wheeler, C. M.
Dubin, G.
Schuind, A.
Zahaf, T.
LANCET, 2009, 374 (9706): : 1975 - 1985
[33] Risk of Spontaneous Abortion in Young Women Exposed to Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine in the United Kingdom: An Observational Cohort Study
Baril, Laurence
Rosillon, Dominique
Willame, Corinne
Angelo, Maria-Genalin
Zima, Julia
van den Bosch, Judith H.
van Staa, Tjeerd
Boggon, Rachel
Bunge, Eveline
Hernandez-Diaz, Sonia
Chambers, Christina
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 491 - 491
[34] EFFICACY, SAFETY AND IMMUNOGENICITY OF THE HPV-16/18 AS04-ADJUVANTED VACCINE IN CHINESE WOMEN: 4-YEAR FOLLOW-UP RESULTS FROM A RANDOMIZED CONTROLLED TRIAL
Zhu, F.
Zhao, F.
Chen, W.
Hu, S.
Hu, Y.
Hong, Y.
Zhang, W.
Li, J.
Zhang, Y.
Zhang, X.
Pan, Q.
Mei, M.
Yang, X.
Yu, J.
Zhang, C.
Tang, H.
He, Y.
Suryakiran, P.
Datta, S.
Bi, D.
Struyf, F.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 1584 - 1585
[35] Vaccination with a Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Cervical Cancer Vaccine in Korean Girls Aged 10-14 Years
Kim, Young-Jae
Kim, Kyung-Tai
Kim, Jae-Hoon
Cha, Soon-Do
Kim, Jae Weon
Bae, Duk-Soo
Nam, Joo-Hyun
Ahn, Woong-Shick
Choi, Ho-Sun
JOURNAL OF KOREAN MEDICAL SCIENCE, 2010, 25 (08) : 1197 - 1204
[36] Randomized Trial: Immunogenicity and Safety of Coadministered Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine and Combined Hepatitis A and B Vaccine in Girls
Pedersen, Court
Breindahl, Morten
Aggarwal, Naresh
Berglund, Johan
Oroszlan, Gyoergy
Silfverdal, Sven Arne
Szuts, Peter
O'Mahony, Michael
David, Marie-Pierre
Dobbelaere, Kurt
Dubin, Gary
Descamps, Dominique
JOURNAL OF ADOLESCENT HEALTH, 2012, 50 (01) : 38 - 46
[37] Impact of HPV-16/18 AS04-adjuvanted vaccine on preventing subsequent infection and disease after excision treatment: post-hoc analysis from a randomized controlled trial
Zhao, Shuang
Hu, Shangying
Xu, Xiaoqian
Zhang, Xun
Pan, Qinjing
Chen, Feng
Zhao, Fanghui
BMC INFECTIOUS DISEASES, 2020, 20 (01)
[38] Impact of HPV-16/18 AS04-adjuvanted vaccine on preventing subsequent infection and disease after excision treatment: post-hoc analysis from a randomized controlled trial
Shuang Zhao
Shangying Hu
Xiaoqian Xu
Xun Zhang
Qinjing Pan
Feng Chen
Fanghui Zhao
BMC Infectious Diseases, 20
[39] High efficacy of a HPV-16/18 L1 virus-like particle (VLP) vaccine adjuvanted with AS04 against CIN2+ caused by HPV-16/18 infection in a broad population of young women
Skinner, S. R.
Garland, S. M.
Denham, I.
O'Sullivan, M.
Waddell, R.
Mindel, A.
SEXUAL HEALTH, 2007, 4 (04) : 305 - 306
[40] Prevalence and Incidence of Human Papillomavirus (HPV) Infection Before and After Pregnancy: Pooled Analysis of the Control Arms of Efficacy Trials of HPV-16/18 AS04-Adjuvanted Vaccine (vol 6, ofz486, 2019)
Chen, Jing
Gopala, Kusuma
Puthatta, Akarsh
Struyf, Frank
Rosillon, Dominique
OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (03):

← 1 2 3 4 5 →